• HotStart Universal 2X FAST Green qPCR Master Mix Workflow

  2026-09-08

  Translate the hly–biofilm findings in Listeria monocytogenes into a practical RT-qPCR workflow for comparing virulence, quorum-sensing, and stress-response transcripts. This guide shows how a fast hot-start polymerase, inhibitor tolerance, ROX normalization, and melt curve analysis can improve confidence in dye-based gene expression analysis.

• Mitomycin C Workflows for DNA Damage Assays

  2026-09-08

  Mitomycin C is an antitumor antibiotic that combines direct DNA adduct stress with strong utility in apoptosis and combination-treatment experiments. This guide translates its chemistry into concentration-response, TRAIL-sensitization, DNA-repair, and biomarker-aware workflows while emphasizing formulation control and assay troubleshooting.

• Alcian Blue & Nuclear Fast Red Staining Kit: Guide

  2026-09-07

  Learn how the Alcian Blue & Nuclear Fast Red Staining Kit pH2.5 distinguishes acid-rich extracellular matrix from cellular morphology. This decision-focused guide connects staining chemistry, chondrogenic assay interpretation, and small-tissue preanalytics without confusing visibility with biological specificity.

• ABT-263 (Navitoclax): From Apoptosis to Translation

  2026-09-07

  ABT-263 (Navitoclax) is more than a potent Bcl-2 family inhibitor: it is a decision tool for mapping mitochondrial dependence, designing stronger apoptosis assays, and testing translational hypotheses across oncology and systemic aging research.

• Luminescent ATP Cell Viability Assay Kit I for Ferroptosis

  2026-09-05

  Discover how the Luminescent ATP Cell Viability Assay Kit I can clarify ATP loss during RSL3-driven ferroptosis research. This article connects mitochondrial zinc biology with rigorous cell viability measurement, assay controls, and interpretation limits.

• WY-14643 (Pirinixic Acid): PPARα Guide

  2026-09-04

  WY-14643, also called Pirinixic Acid, is a selective PPARα agonist used in lipid metabolism regulation, inflammation, and metabolic disorder research. Product data report an IC50 of 10.11 µM against human PPARα, while preclinical evidence supports its use as a mechanistic tool rather than a clinical therapy.

• Mianserin HCl: From Clinical Signal to Assay Logic

  2026-09-04

  Mianserin HCl offers a distinctive way to connect clinical antidepressant evidence with receptor-focused experimental design. This article explains how its 5-HT2 receptor antagonist profile, exposure data, time-course effects, and formulation behavior can improve interpretation in neuroscience and antipathogenic research.

• Metoprolol Tartrate: Selectivity as a Translational Tool

  2026-09-03

  Metoprolol Tartrate offers more than a cardioselective pharmacology control. Its β1 preference provides a strategic way to separate cardiac signaling from β2/β3-dependent tissue responses, including hematopoietic recovery after transplantation.

• Isorhamnetin: Reliable Cellular Assay Design

  2026-09-03

  This scenario-based guide shows how Isorhamnetin (SKU N1358) can be incorporated into reproducible cell viability, oxidative stress, apoptosis, and signaling workflows. It translates concentration, solvent, storage, and interpretation evidence into practical decisions for biomedical laboratories.

• SU6656 Src tyrosine kinases inhibitor: Lab Guide

  2026-09-02

  This scenario-based guide explains how SU6656 Src tyrosine kinases inhibitor, SKU B5839, can be evaluated in proliferation, viability, megakaryocyte maturation, and radiotherapy-related assays. It emphasizes solvent control, endpoint selection, evidence boundaries, and practical product-selection criteria.

• RESTRICT-seq Maps Epigenetic Dependencies in SCC

  2026-09-02

  The RESTRICT-seq preprint presents a time-gated CRISPR screening strategy for separating early and late genetic requirements during squamous cell carcinoma resistance. Its central implication is that epigenetic dependencies may be state- and time-specific, providing a framework for more precise cancer biology research and follow-up pharmacological validation.

• Imipenem Workflows for Antibacterial Research

  2026-09-01

  Imipenem combines broad-spectrum antibacterial activity with a practical water-based workflow for bacterial susceptibility, phagocytosis, and sepsis animal model studies. Its potential extension into antimicrobial-releasing intracortical probes is promising but remains a hypothesis requiring spatially resolved validation.

• Reversine: Aurora Kinase Inhibitor Workflow

  2026-09-01

  Reversine is a research tool for probing Aurora kinase signaling pathway activity, mitotic control, cancer cell proliferation inhibition, and apoptosis-related phenotypes. This guide explains formulation, controls, and interpretation boundaries; it is intended for laboratory research only and not for diagnostic, therapeutic, or medical use.

• RNA Pol II Inhibition and Apoptotic Signaling

  2026-08-31

  Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic response triggered by loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. The study reframes transcription-targeting drug mechanisms and provides a framework for separating polymerase degradation-dependent signaling from passive mRNA and protein depletion.

• MLN8237 (Alisertib) Research Workflows

  2026-08-31

  Build reproducible Aurora A inhibition studies with MLN8237 (Alisertib), from nanomolar cell assays to mechanistic apoptosis and tumor-model validation. This guide connects retinoblastoma findings with practical dosing, controls, storage, and troubleshooting decisions for cancer biology research.

8463 records 1/565 page Next 12345 下5页 Last page